Savara Inc
Savara Inc (SVRA): 6 pipeline candidates · 2 upcoming catalysts · ~18 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.8 months
D/E 0.26 · 24% dilution
Lead: Approved
6 candidates
2 upcoming, next in ~346d
N/A
A transparent, data-derived signal for Savara Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.1B
Cash
$38.8M
Quarterly Burn
$33.0M
Runway
17.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| company's molbreevi | Approved |
| molbreevi | Phase 3 |
| molgramostim | Phase 3 |
| molgramostim inhalation | Phase 3 |
| molgramostim nebulizer | Phase 3 |
| molgramostim open-label | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
180
Total value held
$762.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 15,567,826 | $85.0M |
| deerfield management company, l.p. | 13,569,000 | $74.1M |
| blackrock, inc. | 11,291,185 | $61.6M |
| polar capital holdings plc | 9,541,786 | $52.1M |
| woodline partners lp | 8,490,238 | $46.4M |
| state street corp | 6,707,684 | $36.6M |
| rtw investments, lp | 5,952,380 | $32.5M |
| marshall wace, llp | 4,514,348 | $24.6M |
| geode capital management, llc | 3,594,480 | $19.6M |
| spruce street capital lp | 3,383,175 | $18.5M |
Showing top 10 of 180 institutional holders of Savara Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Savara Inc's pipeline?
Savara Inc (SVRA) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Savara Inc's lead drug candidate?
Savara Inc's most advanced tracked candidate is company's molbreevi (Approved) for aPAP (the "Approval Milestone").
What is Savara Inc's next catalyst?
Savara Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb" — expected May 30, 2027.
What is Savara Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Savara Inc has approximately 17.8 months of cash runway.
What is Savara Inc's market capitalization?
Savara Inc's market capitalization is approximately $1.1B.
Get the full picture on Savara Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.